Sagimet Biosciences

Sagimet Biosciences is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases linked to the overproduction of the fatty acid palmitate. Its lead candidate is denifanstat, an oral once-daily FASN inhibitor in Phase 3 development for MASH, and it is also being studied in oncology and dermatology.